白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展

doi:10.35541/cjd.20201086

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (7): 689-692.doi: 10.35541/cjd.20201086

白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展

蒋晓妍¹ 高敏² 张晓艳³ 刘宁远¹

¹北京中医药大学中日友好临床医学院，北京 100029；²北京大学医学部中日友好临床医学院，北京 100029；³中日友好医院皮肤性病科，北京 100029

收稿日期:2020-11-12 修回日期:2022-03-07 发布日期:2023-07-04
通讯作者: 张晓艳 E-mail:superfawn@aliyun.com
作者简介:4月份能否开具录用通知？2021年11月17日来电咨询能否进款网络首发

Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis

Jiang Xiaoyan¹, Gao Min², Zhang Xiaoyan³, Liu Ningyuan¹

¹China-Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China; ²China-Japan Friendship Clinical Medical College, Peking University Health Science Center, Beijing 100029, China; ³Department of Dermatology and Venereology, China-Japan Friendship Hospital, Beijing 100029, China

Received:2020-11-12 Revised:2022-03-07 Published:2023-07-04
Contact: Zhang Xiaoyan E-mail:superfawn@aliyun.com

摘要/Abstract

摘要： 【摘要】脓疱型银屑病的病情严重，可危及生命，且传统治疗方法疗效欠佳。近年来，白细胞介素17和白细胞介素23拮抗剂在银屑病治疗中发挥出良好作用。本文综述白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病的最新进展。

关键词: 银屑病, 白细胞介素17, 白细胞介素23, 泛发性脓疱型银屑病, 连续性肢端皮炎, 掌跖脓疱病

Abstract: 【Abstract】 Pustular psoriasis is a serious life-threatening disease, and patients usually show poor response to traditional treatments. In recent years, interleukin-17 and interleukin-23 inhibitors have shown favorable efficacy in the treatment of psoriasis. This review summarizes the latest progress in interleukin-17 and interleukin-23 inhibitors for the treatment of pustular psoriasis.

Key words: Psoriasis, Interleukin-17, Interleukin-23, Generalized pustular psoriasis, Acrodermatitis continua of Hallopeau, Palmoplantar pustulosis

蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023,56(7):689-692. doi:10.35541/cjd.20201086

Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.doi:10.35541/cjd.20201086

参考文献 34

［1］	Setta⁃Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis⁃associated pustular phenotypes［J］. J Invest Dermatol, 2013,133（5）:1366⁃1369. doi: 10.1038/jid.2012.490
［2］	Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies［J］. Clin Rev Allergy Immunol, 2018,54（1）:102⁃113. doi: 10.1007/s12016⁃018⁃8668⁃1.
［3］	Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Dermatol, 2017,44（4）:355⁃362. doi: 10.1111/1346⁃8138.13622.
［4］	Okubo Y, Mabuchi T, Iwatsuki K, et al. Long⁃term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Eur Acad Dermatol Venereol, 2019,33（2）:325⁃332. doi: 10.1111/jdv.15287.
［5］	Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab［J］. J Dermatolog Treat, 2021,32（1）:117⁃119. doi: 10.1080/09546634.2019.1628170.
［6］	Pilz AC, Roenneberg S, Biedermann T, et al. Ixekizumab for acrodermatitis continua［J］. J Dtsch Dermatol Ges, 2018,16（7）:907⁃910. doi: 10.1111/ddg.13568.
［7］	Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phase III open⁃label multicenter Japanese study［J］. J Dermatol, 2016,43（9）:1011⁃1017. doi: 10.1111/1346⁃8138.13306.
［8］	Wilsmann⁃Theis D, Schnell LM, Ralser⁃Isselstein V, et al. Successful treatment with interleukin⁃17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations［J］. J Dermatol, 2018,45（7）:850⁃854. doi: 10.1111/1346⁃8138.14318.
［9］	Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis［J］. J Dermatol, 2020,47（3）:e77⁃77e78. doi: 10.1111/1346⁃8138.15228.
［10］	Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work［J］. J Dermatol, 2018,45（11）:1353⁃1356. doi: 10.1111/1346⁃8138.14636.
［11］	Molho⁃Pessach V, Alyan R, Gordon D, et al. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent［J］. JAMA Dermatol, 2017,153（5）:473⁃475. doi: 10.1001/jamadermatol.2016.5705.
［12］	Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report［J］. Acta Derm Venereol, 2020,100（15）:adv00251. doi: 10.2340/ 00015555⁃3611.
［13］	Balestri R, Rech G, Tasin L, et al. Acrodermatitis continua of Hallopeau successfully treated with secukinumab［J］. J Dermatolog Treat, 2018,29（sup1）:3⁃5. doi: 10.1080/09546634. 2018.1527993.
［14］	Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab［J］. JAAD Case Rep, 2017,3（3）:215⁃218. doi: 10.1016/j.jdcr.2017.02.016.
［15］	Smirnova LM, Vertieva EY, Olisova OY, et al. Outcomes of various types of therapy in patients with treatment⁃resistant acrodermatitis continua of Hallopeau［J］. Biologics, 2019,13:83⁃87. doi: 10.2147/BTT.S199100.
［16］	Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial［J］. J Am Acad Dermatol, 2017,76（1）:70⁃80. doi: 10.1016/j.jaad.2016.07.058.
［17］	Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study［J］. Br J Dermatol, 2017,176（3）:741⁃751. doi: 10.1111/bjd. 14702.
［18］	Passante M, Dastoli S, Nisticò SP, et al. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report［J］. Dermatol Ther, 2020,33（1）:e13170. doi: 10.1111/dth. 13170.
［19］	Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab［J］. Eur J Dermatol, 2018,28（4）:538⁃539. doi: 10.1684/ejd.2018.3325.
［20］	Pinter A, Wilsmann⁃Theis D, Peitsch WK, et al. Interleukin⁃17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases［J］. J Dermatol, 2019,46（5）:426⁃430. doi: 10.1111/1346⁃8138.14815.
［21］	Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin⁃23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52⁃week, phase 3, multicenter, open⁃label study［J］. J Dermatol, 2018,45（5）:529⁃539. doi: 10.1111/1346⁃8138.14294.
［22］	Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2019,155（10）:1153⁃1161. doi: 10.1001/jamadermatol.2019.1394.
［23］	Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. doi: 10.1001/jamadermatol. 2017.5937.
［24］	Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status［J］. JAMA Dermatol, 2016,152（7）:825⁃828. doi: 10.1001/jamadermatol. 2016.0751.
［25］	Storan ER, O', Gorman SM, et al. Generalized pustular psoriasis treated with ustekinumab［J］. Clin Exp Dermatol, 2016,41（6）:689⁃690. doi: 10.1111/ced.12868.
［26］	Daudén E, Santiago⁃et⁃Sánchez⁃Mateos D, Sotomayor⁃López E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis［J］. Br J Dermatol, 2010,163（6）:1346⁃1347. doi: 10.1111/j.1365⁃2133.2010.09995.x.
［27］	Palacios⁃Álvarez I, Simal⁃Gómez G, Mas⁃Vidal A, et al. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti⁃TNF agents［J］. J Dtsch Dermatol Ges, 2018,16（5）:611⁃613. doi: 10.1111/ddg.13506.
［28］	Adışen E, Özer İ, Temel B, et al. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti⁃TNF agents［J］. Dermatol Ther, 2017,30（2）doi: 10.1111/dth.12460.
［29］	Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra［J］. Dermatology, 2015,230（2）:97⁃100. doi: 10.1159/000367690.
［30］	Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2330⁃2338. doi: 10.1111/jdv.16265.
［31］	Bertelsen T, Kragballe K, Johansen C, et al. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis［J］. Int J Dermatol, 2014,53（10）:e464⁃e466. doi: 10.1111/ijd.12511.
［32］	Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis［J］. Br J Dermatol, 2010,163（5）:1116⁃1118. doi: 10.1111/j.1365⁃2133.2010.09897.x.
［33］	Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ustekinumab in palmoplantar pustulosis［J］. J Eur Acad Dermatol Venereol, 2018,32（5）:e204⁃204e206. doi: 10.1111/jdv.14718.
［34］	Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. doi: 10.1080/14740338.2020.1785427.

[1]	唐志铭荆梦晴陆鹭单霄张翠侠张晓宇孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650.
[2]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
[3]	闪莹常晓彤左亚刚. 自身免疫性疱病的表位扩展现象[J]. 中华皮肤科杂志, 2023, 56(7): 702-705.
[4]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会空军军医大学西京医院中国银屑病患者饮食指南制订工作组. 中国银屑病患者饮食管理指南（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 389-401.
[5]	金利平朱武鲁艳刘盼盼谭敏佳王英杨晶徐黎聪胡琨匡叶红. 饮食干预治疗银屑病的相关进展[J]. 中华皮肤科杂志, 2023, 56(4): 357-360.
[6]	连盼盼刘军苏忠兰王宏伟. 过氧化物酶体增殖物激活受体γ对皮肤生理功能和病理过程的影响[J]. 中华皮肤科杂志, 2023, 56(4): 365-368.
[7]	阮诗钒张鹏林婷婷罗仁炜鲍思怡薛晨瑶童泽群张亮亮龚婷纪超. 寻常型银屑病与血脂异常的相关性研究[J]. 中华皮肤科杂志, 2023, 0(3): 20220322-e20220322.
[8]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.
[9]	周健俞晨王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察[J]. 中华皮肤科杂志, 2023, 56(3): 247-251.
[10]	胡琨杨晶王巧林陈军臣张谧朱武张斌窦冠珅 Wendong Chen, 匡叶红. [开放获取] 依奇珠单抗治疗银屑病短期疗效的单中心病例回顾性研究[J]. 中华皮肤科杂志, 2023, 56(3): 210-215.
[11]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 0(3): 20210794-e20210794.
[12]	何谐栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 273-278.
[13]	杨琦郑捷. 生物制剂治疗对银屑病相关心血管疾病的影响[J]. 中华皮肤科杂志, 2023, 56(2): 165-169.
[14]	黄贺张学军. 白细胞介素23抑制剂古塞奇尤单抗在银屑病治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(2): 181-184.
[15]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220869-e20220869.

白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展

Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

Metrics

本文评价

推荐阅读 10